Outset Medical, Inc. (NASDAQ:OM) Given Consensus Rating of “Moderate Buy” by Analysts

Outset Medical, Inc. (NASDAQ:OM) has been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $10.00.

Several research firms have recently weighed in on OM. TD Cowen reissued a “buy” rating on shares of Outset Medical in a research report on Friday. BTIG Research dropped their target price on shares of Outset Medical from $17.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Outset Medical in a research report on Friday, March 27th. Finally, Wall Street Zen downgraded shares of Outset Medical from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OM. BML Capital Management LLC grew its position in Outset Medical by 250.2% during the first quarter. BML Capital Management LLC now owns 1,902,201 shares of the company’s stock valued at $7,304,000 after purchasing an additional 1,359,021 shares in the last quarter. Millennium Management LLC grew its position in Outset Medical by 165.8% during the third quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock valued at $5,950,000 after purchasing an additional 262,874 shares in the last quarter. Ensign Peak Advisors Inc grew its position in Outset Medical by 71.8% during the fourth quarter. Ensign Peak Advisors Inc now owns 560,169 shares of the company’s stock valued at $2,078,000 after purchasing an additional 234,082 shares in the last quarter. Alyeska Investment Group L.P. grew its position in Outset Medical by 10.2% during the third quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company’s stock valued at $22,798,000 after purchasing an additional 150,000 shares in the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in Outset Medical during the second quarter valued at approximately $2,750,000.

Outset Medical Stock Down 1.1%

NASDAQ OM opened at $3.65 on Tuesday. The company has a debt-to-equity ratio of 0.87, a current ratio of 6.29 and a quick ratio of 4.97. The company’s 50 day simple moving average is $3.90 and its 200 day simple moving average is $5.09. Outset Medical has a 12 month low of $3.00 and a 12 month high of $21.98. The company has a market capitalization of $67.67 million, a P/E ratio of -0.88 and a beta of 1.92.

Outset Medical (NASDAQ:OM) last released its earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.79) by ($0.04). The firm had revenue of $27.86 million during the quarter, compared to analysts’ expectations of $28.90 million. Outset Medical had a negative return on equity of 56.13% and a negative net margin of 63.65%. Equities research analysts expect that Outset Medical will post -3.83 earnings per share for the current fiscal year.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.